-

Lost Money in BioXcel Therapeutics, Inc? Gibbs Law Group Investigates Potential Securities Law Violations

OAKLAND, Calif.--(BUSINESS WIRE)--Gibbs Law Group reminds investors that a class action lawsuit has been filed against BioXcel Therapeutics, Inc. (NASDAQ: BTAI), on behalf of investors who purchased or acquired shares between December 15, 2021, and June 28, 2023, inclusive. Shares of BioXcel dropped 65% on June 29, 2023, after the company disclosed potential protocol and data integrity issues related to how its safety data was being recorded at a late-stage drug trial testing site. Gibbs Law Group encourages BioXcel investors to contact us to discuss their legal rights and options. Investors have until September 5, 2023, to apply to the court to be appointed as a lead plaintiff in the lawsuit.

To speak with an attorney regarding this class action lawsuit investigation, click here or call (888) 410-2925.

On Thursday, June 29, 2023, shares of biotech company BioXcel dropped 65% after the company disclosed that the principal investigator at its clinical trial site fabricated emails meant to demonstrate that a report detailing an adverse safety event in a patient had been timely reported. Previously, in December 2022, the FDA conducted an on-site inspection and discovered that the same principal investigator may have failed to follow certain protocols, including adhering to the study’s approved consent form and keeping adequate case histories for certain patients.

After BioXcel became aware of the principal investigator’s fabricated emails in May 2023, it launched an investigation and announced a plan to hire an independent auditing group to investigate the issue. According to BioXcel, this may delay “the timing of the Company’s development plans for, and prospects for regulatory approval” of its Alzheimer’s drug, BXCL501, by two to three months, and may lead to “new findings regarding the integrity of the trial data from this principal investigator’s site, the accuracy of safety or efficacy findings, or the usability of the data in connection with a marketing application.”

Following this news, BioXcel’s stock price dropped 65% on June 29, 2023, causing significant harm to investors.

What Should BioXcel Investors Do?

If you invested in BioXcel Therapeutics, visit our website or contact our securities team directly at (888) 410-2925 to discuss how you may be able to recover your losses. Our investigation concerns whether BioXcel Therapeutics, Inc. has violated federal securities laws by providing false or misleading statements to investors.

About Gibbs Law Group

Gibbs Law Group represents investors throughout the country in securities litigation to correct abusive corporate governance practices, breaches of fiduciary duty, and proxy violations. The firm has recovered over a billion dollars for its clients against some of the world’s largest corporations, and our attorneys have received numerous honors for their work, including “Best Lawyers in America,” “Top Plaintiff Lawyers in California,” “California Lawyer Attorney of the Year,” “Class Action Practice Group of the Year,” “Consumer Protection MVP,” and “Top Women Lawyers in California.”

This press release may constitute Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

CATHERINE CONROY
PHONE: 510.350.9705
EMAIL: CRC@CLASSLAWGROUP.COM

Gibbs Law Group

NASDAQ:BTAI

Release Summary
Gibbs Law Group reminds investors to contact us about the BioXcel Therapeutics, Inc. (NASDAQ: BTAI) class action lawsuit.
Release Versions
$Cashtags
Hashtags

Contacts

CATHERINE CONROY
PHONE: 510.350.9705
EMAIL: CRC@CLASSLAWGROUP.COM

More News From Gibbs Law Group

Lost Money in Backward Hat Capital (BH Capital)? Gibbs Mura is Investigating Potential Legal Claims on Behalf of BH Capital Investors

OAKLAND, Calif.--(BUSINESS WIRE)--Gibbs Mura and Silver Law Group are investigating potential legal claims on behalf of people who invested in Backward Hat Capital (“BH Capital”) or its affiliated funds, including Traders Point Capital and AI Capital. Federal authorities allege the firm ran a foreign exchange Ponzi scheme that raised more than $600 million from over 2,000 investors. The potential Backward Hat Capital Class Action Lawsuit aims to help investors to recover losses. YOU MAY BE ABLE...

Lost Money in BillionToOne, Inc. (NASDAQ: BLLN)? Gibbs Mura is Investigating Potential Securities Law Violations on Behalf of BLLN Investors

OAKLAND, Calif.--(BUSINESS WIRE)--Gibbs Mura is investigating a potential securities class action lawsuit on behalf of BillionToOne (BLLN) investors....

Gibbs Mura Files Class Action Against Axon Over License Plate Surveillance

OAKLAND, Calif.--(BUSINESS WIRE)--Gibbs Mura & co-counsel filed a lawsuit against Axon Enterprise alleging it unlawfully collects and shares CA drivers’ data through its ALPR cameras....
Back to Newsroom